Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants

Abstract Repositioning of clinical approved drugs could represent the fastest way to identify therapeutic options during public health emergencies, the majority of drugs explored for repurposing as antivirals for 2019 coronavirus disease (COVID-19) have failed to demonstrate clinical benefit. Without specific antivirals, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to cause major global mortality. Antimalarial drugs, such as chloroquine (CQ)/hydroxychloroquine (HCQ) and mefloquine have emerged as potential anti-SARS-CoV-2 antivirals. CQ/HCQ entered the Solidarity and RECOVERY clinical trials against COVID-19 and showed lack of efficacy. Importantly, mefloquine is not a 4-aminoquinoline like CQ and HCQ and has been previously repurposed for other respiratory diseases. Unlike the 4-aminoquinolines that accumulate in the high pH of intracellular lysosomes of the lung, the high respiratory tract penetration of mefloquine is driven by its high lipophilicity. While CQ and HCQ exhibit activity in Vero E6 cells, their activity is obviated in TMPRSS2-expressing cells, such as Calu-3 cells, which more accurately recapitulate in vivo entry mechanisms for SARS-CoV-2. Accordingly, here we report the anti-SARS-CoV-2 activity of mefloquine in Calu-3 type II pneumocytes and primary human monocytes. Mefloquine inhibited SARS-CoV-2 replication in Calu-3 cells with low cytotoxicity and EC50and EC90values of 1.2 and 5.3 µM, respectively. In addition, mefloquine reduced up to 68% the SARS-CoV-2 RNA levels in infected monocytes, reducing viral-induced inflammation. Mefloquine blocked early steps of the SARS-CoV-2 replicative cycle and was less prone than CQ to induce drug-associated viral mutations and synergized with RNA polymerase inhibitor. The pharmacological parameters of mefloquine are consistent with its plasma exposure in humans and its tissue-to-plasma predicted coefficient points that this drug may accumulate in the lungs. These data indicate that mefloquine could represent an orally available clinically approved drug option against COVID-19 and should not be neglected on the basis of the failure of CQ and HCQ..

Medienart:	Preprint

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	bioRxiv.org - (2023) vom: 05. Jan. Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Beteiligte Personen:

Sacramento, Carolina Q. [VerfasserIn] Fintelman-Rodrigues, Natalia [VerfasserIn] Dias, Suelen S. G. [VerfasserIn] Temerozo, Jairo R. [VerfasserIn] Da Silva, Aline de Paula D. [VerfasserIn] da Silva, Carine S. [VerfasserIn] Ferreira, André C. [VerfasserIn] Mattos, Mayara [VerfasserIn] Soares, Vinicius C. [VerfasserIn] Pereira-Dutra, Filipe [VerfasserIn] Miranda, Milene D. [VerfasserIn] Barreto-Vieira, Debora F. [VerfasserIn] da Silva, Marcos Alexandre N. [VerfasserIn] Santos, Suzana S. [VerfasserIn] Torres, Mateo [VerfasserIn] Rajoli, Rajith K R [VerfasserIn] Paccanaro, Alberto [VerfasserIn] Owen, Andrew [VerfasserIn] Bou-Habib, Dumith Chequer [VerfasserIn] Bozza, Patrícia T. [VerfasserIn] Souza, Thiago Moreno L. [VerfasserIn]

Links:	Volltext [lizenzpflichtig] Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.1101/2021.07.21.451321

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI03224620X